{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:41:29Z","timestamp":1792759289834,"version":"4.5.0"},"reference-count":32,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","award":["MR\/V023373\/1"],"award-info":[{"award-number":["MR\/V023373\/1"]}],"id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Dihydropyridine calcium channel blockers have been implicated in both symptom improvement and exacerbation in pre-existing severe mental illness (SMI). We aimed to test the hypothesis that blood-brain barrier penetrant dihydropyridines (DHPs) reduce rates of mental health hospitalisation and self-harm compared to non-penetrant DHPs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We used English electronic health records (Clinical Practice Research Datalink) to conduct a target trial emulation study in people with schizophrenia, bipolar disorder or other psychosis. We compared admissions for mental health and self-harm in those prescribed blood-brain barrier penetrant (intervention) and non-penetrant DHPs (control). Our primary endpoint was a 12-month intention-to-treat analysis using covariate adjustment. We additionally completed overlap weighting, per-protocol analyses and negative outcome controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We included 918 people prescribed blood-brain barrier penetrant DHPs and 3384 prescribed amlodipine (control). In the primary covariate-adjusted intention-to-treat analysis, there was no clear evidence of a difference in rates of combined mental health admissions and self-harm events (adjusted hazard ratio (HR): 1.22; 95% confidence interval (CI): 0.78\u20131.91 at 12\u2009months). In a pre-specified sensitivity analysis using overlap weighting, self-harm event rates were elevated in the intervention group at 12\u2009months (HR: 2.10; 95% CI: 1.13\u20133.94); however, the equivalent covariate-adjusted estimate showed no clear difference (HR: 1.81; 95% CI: 0.52\u20136.26).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In people with SMI, blood-brain barrier penetrant DHPs were not associated with reduced mental health hospitalisations or self-harm events compared to those treated with amlodipine, though estimates were imprecise. This active comparator design cannot distinguish between absence of effect or equivalent benefit of both drug classes. There are peripheral pathways through which DHPs may impact psychiatric symptoms and these require further exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261473408","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T11:01:15Z","timestamp":1786532475000},"page":"1579-1593","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of adjunctive dihydropyridine calcium channel blockers on mental health outcomes in people with severe mental illness: A target trial emulation in English electronic health records"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-938X","authenticated-orcid":false,"given":"Naomi","family":"Launders","sequence":"first","affiliation":[{"name":"Division of Psychiatry, University College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin","family":"Richards-Belle","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth K. C.","family":"Man","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy, School of Pharmacy, University College London, UK"},{"name":"Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, UK"},{"name":"Li Ka Shing Faculty of Medicine, Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[{"name":"Li Ka Shing Faculty of Medicine, Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong"},{"name":"Advance Data Analytics for Medical Science Limited, Hong Kong Special Administrative Region, China"},{"name":"Aston Centre of Excellence in Pharmacotherapy Optimisation and Pharmacoepidemiology Research, Aston Pharmacy School, Aston University, Birmingham, UK"},{"name":"Macau University of Science and Technology, Hong Kong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2519-1539","authenticated-orcid":false,"given":"David P. J.","family":"Osborn","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, UK"},{"name":"North London NHS Foundation Trust, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-3862","authenticated-orcid":false,"given":"Joseph F.","family":"Hayes","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, UK"},{"name":"North London NHS Foundation Trust, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"crossref","unstructured":"Boal AH Smith DJ McCallum L et al. (2016) Monotherapy with major antihypertensive drug classes and risk of hospital admissions for mood disorders. Hypertension 68(5): 1132\u20131138. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08188","DOI":"10.1161\/HYPERTENSIONAHA.116.08188"},{"key":"e_1_3_4_3_1","doi-asserted-by":"crossref","unstructured":"Burdick KE Millett CE Engel R et al. (2020) A molecular approach to treating cognition in schizophrenia by calcium channel blockade: An open-label pilot study of the calcium-channel antagonist isradipine. Schizophrenia Research: Cognition 21: 100180. https:\/\/doi.org\/10.1016\/j.scog.2020.100180","DOI":"10.1016\/j.scog.2020.100180"},{"key":"e_1_3_4_4_1","doi-asserted-by":"crossref","unstructured":"Carnovale C Peyvandi F Perini G et al. (2023) Antihypertensive drugs and brain function: Mechanisms underlying therapeutically beneficial and harmful neuropsychiatric effects. Cardiovascular Research 119(3): 647\u2013667. https:\/\/doi.org\/10.1093\/cvr\/cvac110.","DOI":"10.1093\/cvr\/cvac110"},{"key":"e_1_3_4_5_1","doi-asserted-by":"crossref","unstructured":"Carr MJ Ashcroft DM Kontopantelis E et al. (2016) The epidemiology of self-harm in a UK-wide primary care patient cohort 2001\u20132013. BMC Psychiatry 16: 53. https:\/\/doi.org\/10.1186\/s12888-016-0753-5","DOI":"10.1186\/s12888-016-0753-5"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","unstructured":"Cashin AG Shalokhon B Gana K et al. (2025) Transparent reporting of observational studies emulating a target trial\u2014The TARGET statement. JAMA 334(12): 1084\u20131093. https:\/\/doi.org\/10.1001\/jama.2025.13350","DOI":"10.1001\/jama.2025.13350"},{"key":"e_1_3_4_7_1","doi-asserted-by":"crossref","unstructured":"Colbourne L Harrison PJ (2022) Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders. Molecular Psychiatry 27(9): 3904\u20133912. https:\/\/doi.org\/10.1038\/s41380-022-01615-6","DOI":"10.1038\/s41380-022-01615-6"},{"key":"e_1_3_4_8_1","doi-asserted-by":"crossref","unstructured":"Colbourne L Luciano S Harrison PJ (2021) Onset and recurrence of psychiatric disorders associated with anti-hypertensive drug classes. Translational Psychiatry 11(1): 319. https:\/\/doi.org\/10.1038\/s41398-021-01444-1","DOI":"10.1038\/s41398-021-01444-1"},{"key":"e_1_3_4_9_1","doi-asserted-by":"crossref","unstructured":"Fan B Zhao JV (2024) Genetic proxies for antihypertensive drugs and mental disorders: Mendelian randomization study in European and East Asian populations. BMC Medicine 22(1): 6. https:\/\/doi.org\/10.1186\/s12916-023-03218-6","DOI":"10.1186\/s12916-023-03218-6"},{"key":"e_1_3_4_10_1","doi-asserted-by":"crossref","unstructured":"Fan X Song X Zhao M et al. (2017) The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatrica Scandinavica 136(5): 465\u2013472. https:\/\/doi.org\/10.1111\/acps.12799","DOI":"10.1111\/acps.12799"},{"key":"e_1_3_4_11_1","doi-asserted-by":"crossref","unstructured":"Fu EL Clase CM Evans M et al. (2021) Comparative effectiveness of renin-angiotensin system inhibitors and calcium channel blockers in individuals with advanced CKD: A nationwide observational cohort study. American Journal of Kidney Diseases 77(5): 719\u2013729.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2020.10.006","DOI":"10.1053\/j.ajkd.2020.10.006"},{"key":"e_1_3_4_12_1","doi-asserted-by":"crossref","unstructured":"Grzymala B Halld\u00f3rsd\u00f3ttir D\u00de \u00deorsteinsson H et al. (2026) Reinventing amlodipine. Journal of Pharmacology and Experimental Therapeutics 393(6): 104900. https:\/\/doi.org\/10.1016\/j.jpet.2026.104900","DOI":"10.1016\/j.jpet.2026.104900"},{"key":"e_1_3_4_13_1","doi-asserted-by":"crossref","unstructured":"Harrison PJ Tunbridge EM Dolphin AC et al. (2020) Voltage-gated calcium channel blockers for psychiatric disorders: Genomic reappraisal. British Journal of Psychiatry 216(5): 250\u2013253. https:\/\/doi.org\/10.1192\/bjp.2019.157","DOI":"10.1192\/bjp.2019.157"},{"key":"e_1_3_4_14_1","doi-asserted-by":"crossref","unstructured":"Hayes JF Lundin A Wicks S et al. (2019) Association of hydroxylmethyl glutaryl coenzyme a reductase inhibitors L-type calcium channel antagonists and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness. JAMA Psychiatry 76(4): 382\u2013390. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3907","DOI":"10.1001\/jamapsychiatry.2018.3907"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"e_1_3_4_16_1","doi-asserted-by":"crossref","unstructured":"Hern\u00e1n MA Wang W Leaf DE (2022) Target trial emulation: A framework for causal inference from observational data. JAMA 328(24): 2446\u20132447. https:\/\/doi.org\/10.1001\/jama.2022.21383","DOI":"10.1001\/jama.2022.21383"},{"key":"e_1_3_4_17_1","doi-asserted-by":"crossref","unstructured":"Herrett E Gallagher AM Bhaskaran K et al. (2015) Data resource profile: Clinical practice research datalink (CPRD). International Journal of Epidemiology 44(3): 827\u2013836. https:\/\/doi.org\/10.1093\/ije\/dyv098","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_3_4_18_1","doi-asserted-by":"crossref","unstructured":"Jiang H Liu M Zhang Y et al. (2025) Psychiatric adverse events associated with dihydropyridine calcium channel blockers: A pharmacovigilance study based on FAERS database. Clinical Neuropharmacology 48(6): 195\u2013202. https:\/\/doi.org\/10.1097\/WNF.0000000000000655","DOI":"10.1097\/WNF.0000000000000655"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","unstructured":"Leucht S Crippa A Siafis S et al. (2020) Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia. American Journal of Psychiatry 177(4): 342\u2013353. https:\/\/doi.org\/10.1176\/appi.ajp.2019.19010034","DOI":"10.1176\/appi.ajp.2019.19010034"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","unstructured":"Li M Yatham LN Bhui KS et al. (2023) A pilot pharmacogenetic study of calcium channel blocker treatment of bipolar mania. Psychiatry Research 326: 115281. https:\/\/doi.org\/10.1016\/j.psychres.2023.115281","DOI":"10.1016\/j.psychres.2023.115281"},{"key":"e_1_3_4_21_1","doi-asserted-by":"crossref","unstructured":"Lintunen J L\u00e4hteenvuo M Tanskanen A et al. (2022) Allopurinol dipyridamole and calcium channel blockers in the treatment of bipolar disorder\u2014A nationwide cohort study. Journal of Affective Disorders 313: 43\u201348. https:\/\/doi.org\/10.1016\/j.jad.2022.06.040","DOI":"10.1016\/j.jad.2022.06.040"},{"key":"e_1_3_4_22_1","unstructured":"NHS Digital (2022) Quality and Outcomes Framework 2021\u20132022. Available at: https:\/\/digital.nhs.uk\/data-and-information\/data-collections-and-data-sets\/data-collections\/quality-and-outcomes-framework-qof (accessed 31 July 2026)."},{"key":"e_1_3_4_23_1","volume-title":"Hypertension: Management of Hypertension in Adults in Primary Care. Quick Reference Guide","author":"NICE","year":"2006","unstructured":"NICE (2006) Hypertension: Management of Hypertension in Adults in Primary Care. Quick Reference Guide. National Institute for Health and Care Excellence."},{"key":"e_1_3_4_24_1","volume-title":"NICE Guideline [NG136]: Hypertension in Adults: Diagnosis and Management","author":"NICE","year":"2023","unstructured":"NICE (2023) NICE Guideline [NG136]: Hypertension in Adults: Diagnosis and Management. National Institute for Health and Care Excellence."},{"key":"e_1_3_4_25_1","doi-asserted-by":"crossref","unstructured":"Ritz B Rhodes SL Qian L et al. (2010) L-type calcium channel blockers and Parkinson disease in Denmark. Annals of Neurology 67(5): 600\u2013606. https:\/\/doi.org\/10.1002\/ana.21937","DOI":"10.1002\/ana.21937"},{"key":"e_1_3_4_26_1","doi-asserted-by":"crossref","unstructured":"Schneeweiss S Rassen JA Brown JS et al. (2019) Graphical depiction of longitudinal study designs in health care databases. Annals of Internal Medicine 170(6): 398\u2013406. https:\/\/doi.org\/10.7326\/M18-3079","DOI":"10.7326\/M18-3079"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","unstructured":"Shahn Z Bate A Ryan PB et al. (2022) Systematically exploring repurposing effects of antihypertensives. Pharmacoepidemiology and Drug Safety 31(9): 944\u2013952. https:\/\/doi.org\/10.1002\/pds.5491","DOI":"10.1002\/pds.5491"},{"key":"e_1_3_4_28_1","doi-asserted-by":"crossref","unstructured":"Thorsteinsson H Bhatt DK Grzymala B et al. (2025) Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis drug-target Mendelian randomization and clinical evidence from medical records. Neuropsychopharmacology 50(7): 1145\u20131155. https:\/\/doi.org\/10.1038\/s41386-025-02062-x","DOI":"10.1038\/s41386-025-02062-x"},{"key":"e_1_3_4_29_1","doi-asserted-by":"crossref","unstructured":"Vahdani B Armani Kian A Esfahani MH et al. (2020) Adjunctive raloxifene and isradipine improve cognitive functioning in patients with schizophrenia: A pilot study. Journal of Clinical Psychopharmacology 40(5): 457\u2013463. https:\/\/doi.org\/10.1097\/JCP.0000000000001274","DOI":"10.1097\/JCP.0000000000001274"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/154733251803000103"},{"key":"e_1_3_4_31_1","doi-asserted-by":"crossref","unstructured":"Wolf A Dedman D Campbell J et al. (2019) Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. International Journal of Epidemiology 48(6): 1740\u20131740g. https:\/\/doi.org\/10.1093\/ije\/dyz034.","DOI":"10.1093\/ije\/dyz034"},{"key":"e_1_3_4_32_1","doi-asserted-by":"crossref","unstructured":"Yang Z Li Y Ren Y et al. (2024) The causal relationship between antihypertensive drugs and depression: A Mendelian randomization study of drug targets. Frontiers in Endocrinology 15: 1411343. https:\/\/doi.org\/10.3389\/fendo.2024.1411343","DOI":"10.3389\/fendo.2024.1411343"},{"key":"e_1_3_4_33_1","doi-asserted-by":"crossref","unstructured":"Ye C Fu Y Zhang L et al. (2024) Causal relationship between genetic proxies for calcium channel blockers and the risk of depression: A drug-target Mendelian randomization study. Frontiers in Psychiatry 15: 1377705. https:\/\/doi.org\/10.3389\/fpsyt.2024.1377705","DOI":"10.3389\/fpsyt.2024.1377705"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261473408","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261473408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:51:46Z","timestamp":1792756306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261473408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/02698811261473408"],"URL":"https:\/\/doi.org\/10.1177\/02698811261473408","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}